注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Lumos Pharma Inc是一家临床阶段的生物制药公司。该公司专注于为罕见病患者识别、获取、开发和商业化产品和疗法。其主要候选产品LUM-201是一种治疗儿童生长激素缺乏症(PGHD)和其他罕见内分泌疾病的药物。LUM-201通过GH促分泌素受体刺激生长激素(GH)。其产品通过增加内源性和搏动性GH分泌的幅度来提供治疗罕见内分泌疾病的差异化作用机制。LUM-201是一种口服小分子,是一种用于罕见内分泌疾病的生长激素促分泌素,可注射重组人生长激素(rhGH)已获批准。其产品以针对与生长激素缺乏相关的罕见疾病的开发项目为特色。其子公司包括NewLink International、BlueLink Pharmaceuticals, Inc、BioProtection Systems Corporation和Lumos Pharma Sub, Inc。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
An van Es-Johansson | 61 | 2021 | Independent Director |
Thomas A. Raffin | 74 | 1999 | Lead Independent Director |
Lota S. Zoth | 61 | 2012 | Independent Director |
Chad Allen Johnson | 42 | 2018 | Independent Director |
Mark A. Bach | 64 | 2021 | Scientific Advisory Board Member |
Kevin M. Lalande | 49 | 2014 | Independent Director |
Reiko Horikawa | - | - | Member of Scientific Advisory Board |
Joseph S. McCracken | 68 | 2020 | Independent Director |
George Werther | - | - | Member of Scientific Advisory Board |
Peter Clayton | - | - | Member of Scientific Advisory Board |
Ron Rosenfeld | - | - | Member of Scientific Advisory Board |
Richard J. Hawkins | 74 | 2011 | Founder, CEO & Chairman |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核